Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : XOMA. Bull or Bear? -- Ignore unavailable to you. Want to Upgrade?

To: Maxer who wrote (5513)	2/9/1998 12:57:00 AM
From: Tharos	Read Replies (1) \| Respond to of 17367

Max, Very interesting link. Xoma's results perhaps highlight the need for a different way to value entrepreneurial activities. Many of the factors just do not apply, like P/E for instance. What would be very interesting would be to examine ratings based on Microsoft of 1981, or of Amgen of the same time period. I think if this data existed it would prove my point about valuation difficulties re entrepreneurial firms and cast doubt on VectorVest's valuation algorithm re this type of firm. This is not to cast doubt on their algorithm in general, just bio-techs without developed products.